Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Tanja FehmVolkmar MuellerMaggie Banys-PaluchowskiPeter A FaschingThomas W P FriedlAndreas HartkopfJens HuoberChristian LoehbergBrigitte RackSabine RiethdorfAndreas SchneeweissDiethelm WallwienerFranziska Meier-StiegenNatalia KrawczykBernadette JaegerFlorian ReinhardtOliver HoffmannLothar MuellerPauline WimbergerEugen RuckhaeberleJens-Uwe BlohmerJan-Philipp CieslikAndré FrankenDieter NiederacherHans NeubauerKlaus PantelWolfgang Janninull nullPublished in: Clinical chemistry (2024)
DETECT III is the first clinical study indicating that phenotyping of CTCs might have clinical utility for stratification of MBC cancer patients to HER2-targeting therapies. The OS benefit could be related to lapatinib, but further studies are required to prove this clinical observation. ClinicalTrials.gov Registration Number: NCT01619111.